- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -

- Additional data demonstrate continued capsid innovation via muscular and neuromuscular targeting, immune evasion, and manufacturability -

LEXINGTON, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced eight oral and poster presentations at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 2026 Annual Meeting taking place in Boston, May 11-15, 2026. Voyager's investigational tau-silencing gene therapy VY1706 for Alzheimer's disease, for which Voyager anticipates submitting an investigational new drug (IND) application in Q2 2026 to support projected first-in-human dosing in the second half of 2026, will be featured in a late-breaking presentation of three-month good laboratory practice (GLP) toxicology data.